Surveillance of Antimicrobial Consumption

In Primary Care

2026 Quarter 2

Key Points


  • The rate of antimicrobial consumption in primary care in Ireland during the second quarter (Q2) of 2026 was 19.1 defined daily doses (DDD) per 1,000 inhabitants per day (DID). This represents an increase compared with the same period in 2025, when consumption was 18.6 DID. The annual consumption rate to date is 19.9 DID.

  • Tetracycline consumption reached 4.8 DID in Q1 2026, the highest level ever recorded for a single quarter. Although consumption decreased to 4.3 DID in Q2, this remains the highest tetracycline consumption rate recorded for a second quarter. The annual tetracycline consumption rate to date is 4.6 DID, also the highest level recorded to date. Lymecycline consumption in particular increased from 0.78 DID in Q2 2025 to 1.07 DID in Q2 2026. A similar increase was observed for doxycycline, with consumption rising from 2.84 DID to 3.08 DID between the second quarters of 2025 and 2026.

  • Penicillin consumption decreased between Q2 2025 and Q2 2026, falling from 10.6 DID to 9.5 DID. Excluding the pandemic years, this is the lowest Q2 consumption level for penicillins recorded in the past 10 years. The decrease was primarily driven by reduced consumption of the amoxicillin-clavulanic acid combination. Consumption of this agent declined from 2.51 DID in Q2 2025 to 2.17 DID in Q2 2026.

  • Trimethoprim consumption continued to decline. Consumption during the second quarter was 0.63 DID in both 2021 and 2022 and then decreased steadily each year, reaching 0.43 DID in Q2 2026. This represents a 31.7% decrease over the past five years.

  • A similar trend was observed for nitrofurantoin. Consumption remained relatively stable at around 1.25 DID between the second quarters of 2021 and 2023. However, consumption began to decline after 2023 and reached 0.94 DID in Q2 2026. This represents an almost 25% decrease over the past four years.

  • Consumption of all other agents remained relatively stable between Q2 2025 and Q2 2026.


Methodology

Background

Antimicrobial consumption is the main driver of antimicrobial resistance. Therefore, antimicrobial consumption surveillance is important to identify potential over and inappropriate use of antimicrobial agents.

ATC/DDD Methodology

Irish antimicrobial sales data are obtained from IQVIA (formerly IMS Health), a pharmaceutical market research company. This dataset contains regional, monthly wholesaler-to-community pharmacy sales data from over 95% of the wholesalers and manufacturers in Ireland.

Consumption is measured as defined daily dose (DDD), which is the assumed average maintenance dose per day for a drug used for its main indication in adults. The WHO Anatomical Therapeutic Chemical (ATC) index is used to categorise antimicrobial agents. The ATC/DDD system is recommended by WHO as the international standard for drug utilization studies and it serves as a tool for drug utilization monitoring and research to improve quality of drug use. More information on ATC/DDD Methodology can be found on WHO’s website.

Consumption rates are calculated as DDD per 1000 inhabitants per day (DID). Eurostat yearly population estimates are used for national rates. Central Statistics Office 2022 Census results are proportionated with Eurostat population to calculate the county rates. The underlying trend on the quarterly graph is derived by using local regression of seasonal results.

The WHO introduced the AWaRe classification in 2017 as part of its Essential Medicines List to support antimicrobial stewardship activities. This system categorizes antibiotics into three groups—Access, Watch, and Reserve—to promote their responsible use. To assess the relative consumption of these categories, the 2025 AWaRe classification is applied. By 2030, the EU aims for at least 65% of total antibiotic consumption to come from the Access group in every Member State.

The European Surveillance of Antimicrobial Consumption Network (ESAC-Net) is managed by the European Centre for Disease Prevention and Control (ECDC) and the network uses the same methodology. The country rates for the EU Member States are obtained from ECDC’s ESAC-Net Dashboard. More information on ESAC-Net can be found on ECDC’s website.

Limitations

Although the IQVA database used in this report is very comprehensive, there are some limitations. The data are based on pharmacy wholesale data, rather than on individual prescriptions. Thus, it cannot be used to determine the actual number of antimicrobial courses taken and does not provide information on dose or duration of therapy. Factors such as stockpiling of antimicrobials in pharmacies and drug wastage (e.g. passing the sell-by date) may introduce biases. Likewise, recent changes to prescribing guidelines, that recommend using higher doses may lead to an increase in consumption (as measured by DDD/1000 inhabitants/day), while the total number of prescriptions may have remained static or even declined.


Main Results



Table 1: Antibiotic Consumption in the Last 5 Years by ATC-3 Groups

ATC-3 Name

2022

2023

2024

2025

2026

J01A Tetracyclines

3.8

3.9

4.2

4.1

4.6

J01C Beta-Lactam Antibacterials, Penicillins

10.4

10.5

10.4

9.8

9.0

J01D Other Beta-Lactam Antibacterials

1.3

0.5

0.8

1.1

1.1

J01E Sulfonamides and Trimethoprim

0.8

0.9

0.8

0.8

0.8

J01F Macrolides, Lincosamides, and Streptogramins

3.4

3.1

3.3

3.0

2.9

J01G Aminoglycoside Antibacterials

0.0

0.0

0.0

0.0

0.0

J01M Quinolone Antibacterials

0.4

0.4

0.3

0.3

0.3

J01X Other Antibacterials

1.4

1.3

1.2

1.2

1.4

Total Consumption

21.5

20.6

21.0

20.2

19.9





Seasonal (Quarterly) Results



Table 2: Quarterly (Seasonal) Consumption of Antibiotics in the Last 5 Years

Year

Q1

Q2

Q3

Q4

Rate

2022

18.7

19.9

18.2

29.1

21.4

2023

21.2

19.1

19.0

23.2

20.6

2024

21.6

20.1

19.2

23.3

21.0

2025

21.6

18.6

17.5

23.0

20.2

2026

20.7

19.1

19.9



Tetracyclines



Table 3: Consumption of Tetracyclines (J01A) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

3.8

3.8

3.1

4.6

2023

4.0

3.6

3.7

4.4

2024

4.4

4.2

3.7

4.5

2025

4.5

3.8

3.5

4.5

2026

4.8

4.3


Penicillins



Table 4: Consumption of Penicillins (J01C) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

8.3

9.2

8.7

15.2

2023

10.7

9.5

9.5

12.4

2024

10.8

9.8

9.0

12.0

2025

10.6

8.9

8.2

11.5

2026

9.3

8.6


Other Beta-Lactams



Table 5: Consumption of Other Beta-Lactams (J01D) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

1.1

1.2

1.1

1.9

2023

0.5

0.5

0.5

0.5

2024

0.6

0.6

0.9

1.1

2025

1.1

1.0

1.0

1.2

2026

1.1

1.0


Macrolides



Table 6: Consumption of Macrolides (J01F) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

2.9

3.2

2.8

4.6

2023

3.3

3.0

2.8

3.3

2024

3.2

3.3

3.2

3.4

2025

3.2

2.7

2.6

3.4

2026

3.0

2.8


Sulfonamides and Trimethoprim



Table 7: Consumption of Sulfonamides and Trimethoprim (J01E) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

0.9

0.9

0.7

0.9

2023

1.0

0.9

0.7

0.8

2024

1.0

0.7

0.8

0.8

2025

0.8

0.8

0.8

0.8

2026

0.8

0.7


Quinolones



Table 8: Consumption of Quinolones (J01M) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

0.4

0.4

0.4

0.4

2023

0.4

0.4

0.3

0.4

2024

0.4

0.3

0.3

0.3

2025

0.3

0.3

0.3

0.3

2026

0.3

0.3


Other Antibacterials



Table 9: Consumption of Other Antibacterials (J01X) in the Last 5 Years by Quarters

Year

Q1

Q2

Q3

Q4

2022

1.3

1.2

1.4

1.5

2023

1.3

1.3

1.4

1.4

2024

1.2

1.1

1.3

1.2

2025

1.1

1.1

1.1

1.4

2026

1.3

1.4


Results by Counties





Tetracyclines



Penicillins



Other Beta-Lactams



Macrolides



Sulfonamides and Trimethoprim



Quinolones



Other Antibacterials



Results by CHOs and RHAs


Table 10: Overall Antibiotic Consumption in the Latest Year by CHO Areas

CHO Area

LHO Area

Q1

Q2

Q3

Q4

Rate

1

Donegal LHO, Sligo/Leitrim/West Cavan LHO and Cavan/Monaghan LHO

21.4

20.2

20.8

2

Galway LHO, Roscommon LHO and Mayo LHO

21.1

20.0

20.5

3

Clare LHO, Limerick LHO and North Tipperary/East Limerick LHO

23.9

22.0

22.9

4

Kerry LHO, North Cork LHO, North Lee LHO, South Lee LHO and West Cork LHO

21.9

19.5

20.7

5

South Tipperary LHO, Carlow/Kilkenny LHO, Waterford LHO and Wexford LHO

22.4

20.1

21.3

6

Wicklow LHO, Dún Laoghaire LHO and Dublin South East LHO

22.7

21.1

21.9

7

Kildare/West Wicklow LHO, Dublin West LHO, Dublin South City LHO and Dublin South West LHO

17.3

16.5

16.9

8

Laois/Offaly LHO, Longford/Westmeath LHO, Louth LHO and Meath LHO

20.7

19.6

20.2

9

Dublin North LHO, Dublin North Central LHO and Dublin North West LHO

17.6

16.3

17.0


Table 11: Overall Antibiotic Consumption in the Latest Year by RHAs

RHA

HSE Area

Q1

Q2

Q3

Q4

Rate

Area A

HSE Dublin & NE

18.6

17.3

18.0

Area B

HSE Dublin & Midlands

19.1

18.1

18.6

Area C

HSE Dublin & SE

22.2

20.3

21.3

Area D

HSE SW

21.9

19.5

20.7

Area E

HSE MW

23.9

22.0

22.9

Area F

HSE W & NW

21.1

20.1

20.6

Monthly Comparison


Tetracyclines



Penicillins



Other Beta-Lactams



Macrolides



Sulfonamides and Trimethoprim



Quinolones



Other Antibacterials



International Comparison